IOVA as reported
Iovance Biotherapeutics, Inc. reported $286M of revenue over the trailing twelve months, +34% on the year before. 10 reported series are charted on this page, each one as filed.
$286M
Revenue, trailing twelve months · to Q1 2026 · +34% against the twelve months before
- Net Income
- −$354M
Net Income · −5.7% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$305M
Free Cash Flow · −12% year on year · trailing twelve months to Q1 2026
- Op Margin
- −132%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $286M | +34% | Q1 2026 |
| Net Income | −$354M | −5.7% | Q1 2026 |
| EPS | −$1.22 | n/a | Q2 2025 |
| Gross Margin | 35% | n/a | Q1 2026 |
| Op Margin | −132% | n/a | Q1 2026 |
| Net Margin | −129% | n/a | Q1 2026 |
| ROE | −54% | n/a | Q1 2026 |
| ROA | −42% | n/a | Q1 2026 |
| ROIC | −78% | n/a | Q1 2026 |
| Free Cash Flow | −$305M | −12% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Iovance Biotherapeutics, Inc. (IOVA) - Revenue & ProfitRevenue & ProfitIovance Biotherapeutics, Inc. (IOVA)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com